Hepatitis C Virus (HCV) Infection Pipeline Therapies 2025: Over 20 Companies Driving Innovation Across 20+ Therapies | DelveInsight

According to DelveInsight's evaluation, the global Hepatitis C Virus (HCV) Infection pipeline features more than 20 prominent pharmaceutical and biotechnology companies actively engaged in the development of over 20+ therapeutic candidates. The analysis spans clinical trial activity, therapeutic approaches, mechanisms of action, routes of administration, and recent developments shaping the Hepatitis C Virus Infection treatment landscape.

The "Hepatitis C Virus Infection Pipeline Insight, 2025" report published by DelveInsight delivers an in-depth overview of the current clinical development environment while highlighting future growth opportunities within the Hepatitis C Virus Infection market.

This pipeline report provides a comprehensive commercial and clinical evaluation of therapeutic candidates ranging from the discovery and preclinical stages to late-stage and marketed products. It includes detailed drug profiles covering mechanisms of action, clinical trial outcomes, regulatory milestones such as NDA approvals (where applicable), and ongoing product development activities. Additionally, the report examines strategic initiatives including technology advancements, partnerships, mergers and acquisitions, funding activities, regulatory designations, and other key developments related to product advancement.

Request for Free Sample Report to know details about emerging therapies: https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Hepatitis C Virus Infection Pipeline Report
• Pharmaceutical companies worldwide continue to make substantial progress in developing innovative therapies for Hepatitis C Virus Infection, achieving notable success over recent years.
• Major players involved in Hepatitis C Virus Infection treatment development include Dongguan HEC TaiGen Biopharmaceuticals, Cocrystal Pharma, AbbVie, Janssen Infectious Diseases, Gilead Sciences, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, among others.
• Several promising therapies currently undergoing clinical evaluation-such as TG-2349, CC-31244, Glecaprevir/Pibrentasvir (GLE/PIB), Simeprevir, LDV/SOF, EBR/GZR (50 mg/100 mg) fixed-dose combination, Daclatasvir, and others-are anticipated to significantly influence the Hepatitis C Virus Infection market in the coming years.
• In March 2025, Atea Pharmaceuticals plans to launch two parallel Phase III clinical trials assessing its investigational combination of bemnifosbuvir and ruzasvir for hepatitis C treatment. One study will be conducted across clinical sites in the United States and Canada, while the second trial will involve participants outside North America. Both studies will benchmark the investigational regimen against Epclusa (sofosbuvir/velpatasvir), an approved standard-of-care therapy, with patient enrollment expected to commence in April.
• In July 2024, the World Health Organization (WHO) prequalified the first-ever self-testing kit for hepatitis C. HCV is a bloodborne virus that can cause both acute and chronic liver disease, potentially leading to severe complications such as cirrhosis and liver cancer. Transmission commonly occurs through unsafe injection practices, inadequate medical procedures, unscreened blood transfusions, injection drug use, or blood-exposure-related sexual contact. While no vaccine is currently available, antiviral therapies are capable of curing approximately 95% of HCV infections.

Hepatitis C Virus Infection Overview
Hepatitis C Virus Infection is a liver disorder caused by the hepatitis C virus, primarily transmitted through contact with contaminated blood. Common routes of transmission include shared needles, unscreened blood transfusions, and improperly sterilized medical equipment. The infection may present as acute or chronic; although some acute cases resolve without intervention, chronic infection can progress to serious liver conditions such as fibrosis, cirrhosis, and hepatocellular carcinoma.

Request a Free Sample PDF to learn more about the Hepatitis C Virus Infection Pipeline Therapeutic Assessment: https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Hepatitis C Virus Infection Therapies Across Development Stages
• TG-2349 - Dongguan HEC TaiGen Biopharmaceuticals
• CC-31244 - Cocrystal Pharma
• Glecaprevir/Pibrentasvir (GLE/PIB) - AbbVie
• Simeprevir - Janssen Infectious Diseases
• LDV/SOF - Gilead Sciences
• EBR/GZR (50 mg/100 mg) FDC - Merck Sharp & Dohme LLC
• Daclatasvir - Bristol-Myers Squibb

Routes of Administration
The Hepatitis C Virus Infection pipeline analysis categorizes therapies based on their routes of administration, including:
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type Classification
Pipeline candidates are also segmented by molecular type, such as:
• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies

Hepatitis C Virus Infection Pipeline Therapeutics Evaluation
• Assessment by product type
• Analysis by development stage and product type
• Evaluation by route of administration
• Stage-wise assessment by route of administration
• Classification by molecule type
• Stage-wise assessment by molecule type

DelveInsight's report analyzes more than 20 therapeutic candidates across multiple development stages, including:
• Phase III (late-stage) therapies
• Phase II (mid-stage) therapies
• Phase I (early-stage) therapies
• Preclinical and discovery-stage programs
• Discontinued and inactive candidates
• Route-of-administration-based classifications
The report provides comprehensive profiles of each candidate therapy.

To gain deeper insights into emerging Hepatitis C Virus Infection treatments, download the full pipeline report here:
https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Companies in the Hepatitis C Virus Infection Therapeutics Market
Leading organizations involved in developing Hepatitis C Virus Infection therapies include Sunshine Lake Pharma Co., Ltd., GeneCure Biotechnologies, Biotron, Cocrystal Pharma, Genecure Biotechnologies (Preclinical), iQur, Atea Pharmaceuticals, Dongguan HEC TaiGen Biopharmaceuticals, Nanjing Sanhome Pharmaceutical, and others.

Hepatitis C Virus Infection Pipeline Analysis
The pipeline report offers detailed insights into:
• Companies actively developing Hepatitis C Virus Infection therapies and the number of candidates per organization
• Classification of therapeutic candidates into early-, mid-, and late-stage development
• Targeted therapy programs, including both active and discontinued projects
• Drugs segmented by development stage, route of administration, molecular type, target receptor, mechanism of action, and monotherapy or combination therapy
• In-depth analysis of collaborations, licensing agreements, and funding activities supporting future market growth
The report is compiled using information sourced from DelveInsight's proprietary databases, company and academic institution websites, clinical trial registries, conference proceedings, SEC filings, investor presentations, and publicly available press releases, along with trusted third-party industry sources.

Download the Sample PDF to explore Hepatitis C Virus Infection drugs and therapies in detail: https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hepatitis C Virus Infection Pipeline Market Drivers
• Increasing global prevalence of HCV
• Continued advancements in antiviral therapies
• Strong global health initiatives
• Improved diagnostic technologies
• Growing focus on pan-genotypic treatment options

Hepatitis C Virus Infection Pipeline Market Challenges
• High treatment costs
• Absence of a preventive vaccine
• High proportion of asymptomatic cases
• Emergence of drug resistance
• Gaps in healthcare infrastructure

Scope of the Hepatitis C Virus Infection Pipeline Report
• Geographical Coverage: Global
• Key Companies: Dongguan HEC TaiGen Biopharmaceuticals, Cocrystal Pharma, AbbVie, Janssen Infectious Diseases, Gilead Sciences, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, and others
• Key Therapies: TG-2349, CC-31244, Glecaprevir/Pibrentasvir (GLE/PIB), Simeprevir, LDV/SOF, EBR/GZR (50 mg/100 mg) FDC, Daclatasvir, among others
• Therapeutic Assessment: Marketed and emerging Hepatitis C Virus Infection therapies
• Market Dynamics: Key drivers and barriers influencing market growth

Request a Sample PDF for detailed Hepatitis C Virus Infection pipeline assessment and clinical trial insights:
https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.